On July 18, 2022 Curaleaf International (the "Company" or "Group"), Europe’s largest vertically integrated cannabis company, reported that it has appointed Miles Worne as President, effective 11 July 2022 (Press release, EMMAC Life Sciences, JUL 18, 2022, View Source [SID1234616722]). Antonio Costanzo, the Company’s former CEO, will remain with the Company in a consultancy capacity, with his role transitioning to focus on M&A and Regulatory Affairs. Mr Worne’s appointment as President is part of the Company’s long-term strategy to drive growth as the European cannabis market opens up to adult-use, as well to ensure continued expansion in the medical cannabis market. The appointment of a President reflects Curaleaf’s commitment to capitalise on the ever-changing landscape and opportunities within the international cannabis marketplace.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Miles Worne has significant experience in building consumer brands and joins Curaleaf International from Glanbia plc, where he was European Managing Director of Glanbia Performance Nutrition, the global leader in sports nutrition and weight management. During the past four years at Glanbia, Mr. Worne grew brands such as Slimfast, Body & Fit, Optimum Nutrition and Amazing Grass across European markets.

There is meaningful momentum and a growing acceptance for cannabis in Europe, and a recent European wide poll conducted by Hanway Associates, an advisory firm specialising in strategy, research and M&A in the cannabis sector, demonstrated that more than half of Europeans in eight countries support adult-use cannabis legalisation and support the highest levels of regulation. Of particular importance to European consumers was companies’ adherence to the highest standard of service and regulation in their approach to legal recreational cannabis in a regulated retail offering. In addition to the growing acceptance amongst consumers for recreational cannabis, several governments in Europe have taken steps towards legalising cannabis. Notably Germany’s government has committed to legalising recreational cannabis and as it represents the largest economy in Europe, this presents a significant inflection point for European adult-use. In addition, Spain recently announced it will be creating regulations to allow medical cannabis, and Switzerland has removed medical cannabis access limitations following a rise in demand.

Antonio Costanzo, Former CEO of Curaleaf International, said: "It has been an honour to have co-founded and served as CEO of Curaleaf International since the Company’s inception in 2018. In that short time we have built Europe’s largest vertically integrated cannabis company, culminating in the acquisition by Curaleaf Holdings in 2021. I look forward to working with Miles and the wider team as we take the Company forward to its next stage of development and growth. The market is evolving considerably with significant opportunities across Europe, and I look forward to applying my significant regulatory and M&A experience to help drive the company forward as the global industry leader."

Miles Worne, President of Curaleaf International, said: "I am delighted to join Europe’s largest vertically integrated cannabis company, which already has a market-leading medical cannabis offering. I believe Curaleaf International is ideally positioned to leverage the growing European recreational opportunity and will utilise my significant experience of building strong consumer brands in Europe to help take advantage of the growing momentum in the cannabis industry. I look forward to working with my new colleagues at Curaleaf International in this incredibly exciting period for cannabis in Europe."

Matt Darin, CEO of Curaleaf Holdings, Inc., added, "I would like to welcome Miles Worne as President of Curaleaf International. Miles’s expertise in building strong household name global consumer brands will be invaluable as the European cannabis opportunity continues to evolve. We are extremely excited by the growing opportunity for cannabis across Europe and beyond, and are bullishly optimistic for the next few years as cultural and government acceptance grows. I would also like to thank Antonio Costanzo for what he has achieved as CEO of Curaleaf International, in building Europe’s largest vertically integrated cannabis company. Antonio’s experience in M&A and regulatory savvy will be invaluable to Curaleaf International as we capitalise on the growing European opportunity."

On July 18, 2022 Emergent BioSolutions Inc. (NYSE: EBS) reported that it will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the third quarter of 2022, and financial outlook for full year 2022 (Press release, Emergent BioSolutions, JUL 18, 2022, View Source [SID1234616721]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information
Participants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

On July 18, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported that it has entered into a securities purchase agreement with certain accredited investors for a private placement transaction (the "Private Placement") (Press release, Delcath Systems, JUL 18, 2022, View Source [SID1234616720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

Delcath will issue and sell 690,954 shares of its common stock (the "Common Stock") at a price per share of $3.98, or, in lieu of shares of Common Stock, 566,761 pre-funded warrants to purchase Common Stock (the "Pre-Funded Warrants") at a price per Pre-Funded Warrant of $3.97. The Pre-Funded Warrants will have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full.

Delcath expects to receive gross proceeds from the Private Placement of approximately $5.0 million before deducting offering expenses payable by Delcath. Delcath intends to use the net proceeds from the Private Placement for working capital purposes and other general corporate purposes. The Private Placement is expected to close on or about July 20, 2022, subject to the satisfaction of customary closing conditions.

The securities to be sold in the Private Placement, including the shares of common stock underlying the Pre-Funded Warrants, have not been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. Delcath has agreed to file one or more registration statements with the SEC registering the resale of the Common Stock and the shares issuable upon exercise of the Pre-Funded Warrants purchased in the Private Placement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

July 18, 2022 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, reported that the Company has filed articles of amendment, to effect the previously announced share consolidation (or reverse stock split) (the "Consolidation") of its issued and outstanding common shares (the "Common Shares") on the basis of one post-Consolidation Common Share for every twenty-five pre-Consolidation Common Shares (Press release, AEterna Zentaris, JUL 18, 2022, View Source [SID1234616719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aeterna expects that the price of its Common Shares will reflect the Consolidation by July 21, 2022, marking a positive outcome for the Company as it works to further its development pipeline. Aeterna’s board of directors also thanks all shareholders for their support of the Consolidation initiative.

The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 121,397,007 Common Shares to approximately 4,855,876 Common Shares. The Common Shares are expected to commence trading on the Toronto Stock Exchange (the "TSX") and on the Nasdaq Capital Market (the "Nasdaq") on a post-Consolidation basis on or about the opening of trading on July 21, 2022.

Remaining listed on Nasdaq is important to the Company’s performance, corporate visibility as well as overall awareness of Aeterna to current and potential investors. Aeterna proceeded with the Consolidation in order to satisfy Nasdaq’s minimum bid price requirement. Under this rule, if the Company fails to meet a minimum bid price for its common shares above US$1.00, for a minimum of at least ten consecutive days before July 25, 2022, the Company could be subject to delisting from Nasdaq unless the Company timely requests a hearing before a Nasdaq Hearings Panel. While the Consolidation is expected to result in Aeterna’s Common Shares achieving the requisite minimum bid price by later this week, the Company will not meet the requirement for the Common Shares to trade at this level for a minimum of ten consecutive days before July 25, 2022. However, Aeterna expects to be in full compliance with Nasdaq Listing Rules by August 3, 2022, having traded for a minimum of ten consecutive business days at or above $1.00 per Common Share by that date.

Given that the Company does not expect to trade at or above $1.00 per Common Share for ten consecutive trading days by July 25, 2022, the current expiration date of its grace period, the Company expects to receive a notice of delisting during the week of July 25, 2022. Such notice would afford the Company seven calendar days to request a hearing. If the Company has not been deemed in compliance by the due date for requesting a hearing, the Company intends to timely request a hearing. The hearing request will automatically stay any suspension or delisting action pending the conclusion of the hearings process. Should the Company regain compliance after it has requested a hearing, the Company expects that the hearing will be canceled, provided it meets all other requirements for continued listing at the time. At present, the Company meets all other requirements for continued listing, with the exception of the bid price requirement.

The Company’s transfer agent, Computershare Investor Services Inc., will be sending a letter of transmittal to the registered holders of Common Shares. The letter of transmittal will contain instructions on how to surrender Common Share certificate(s) representing pre-Consolidation Common Shares to the transfer agent. Shareholders may also obtain a copy of the letter of transmittal by accessing the Company’s SEDAR profile at www.sedar.com or the Company’s EDGAR profile at www.sec.gov. Until surrendered, each certificate representing pre-Consolidation Common Shares will be deemed for all purposes to represent the number of Common Shares to which the holder thereof is entitled as a result of the Consolidation. If shareholders hold their Common Shares through an intermediary and they have questions in this regard, they are encouraged to contact their intermediaries.

The Company’s new CUSIP number is 007975501 and its new ISIN number is CA0079755017.

For additional information regarding the Consolidation, please refer to the Company’s Notice of Annual General and Special Meeting of Shareholders and Management Information Circular dated May 16, 2022, which are available on SEDAR at www.sedar.com or EDGAR at www.sec.gov.

On July 18, 2022 THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, reported its half-year revenue and cash position on June 30, 2022, data that is currently being audited (Press release, Theradiag, JUL 18, 2022, View Source [SID1234616717]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Over the six months to June 30, 2022, Theradiag generated revenue of €6.3 million, compared with €5.5 million in the first half of 2021, giving growth of 14.3%.

Theranostics activity recorded another semester of solid growth, with revenue increasing by 9.3% to more than €3.0 million on June 30, 2022. This activity keeps on growing thanks to dynamic sales of the automated i-Track10 driven by an expanding range of i-Tracker tests adapted to this analyzer that thus allows the development of individualized therapeutic monitoring of even more biotherapies.

In France, Theranostics saw a solid level of activity with sales increasing by 10.5% to over €1 million. Abroad, Theranostics activity also generated satisfactory sales of approximately €2.0 million, up 8.7% compared with the first half of 2021. Moreover, the Company is in a period of reflection in order to optimize its commercial activities on the North American market.

IVD (In Vitro Diagnostics) activity recorded strong sales growth of 19.3% to over €3.2 million on June 30, 2022. This activity achieved a particularly noteworthy performance in France, where sales jumped by 29.3% to €2.1 million. These exceptional performances are the result of non-recurrent commercial opportunities. Indeed, during the first half of this year, Theradiag recorded some opportunistic sales of diagnostic instruments, notably to the veterinary sector, and logged sales of genetic tests that were temporarily increased before the closure and resumption of this distribution line.

Cash position

Theradiag had a net cash position of €6.0 million on June 30, 2022, versus €7.1 million on December 31, 2021. This level is in line with the Company’s roadmap outlined at the time of the rights issue carried out in October 2021.

Bertrand de Castelnau, Theradiag’s CEO, commented: "Theradiag is continuing to record solid commercial performances in the first half of 2022. We were able to maintain our customary growth in Theranostics and make the most of market opportunities in in vitro diagnostics. Along with this good sales dynamic, strategic and structural milestones were achieved by the Company in terms of R&D, such as the launch of ez-Track1 that is accelerating our differentiation in biotherapy monitoring and strengthening our leadership position on this market. Moreover, Theradiag has taken the implementation of IVDR* onboard and is focusing its attention on the next measures imposed by this new regulation. In the second half of 2022, we will strive to continue implementing our strategic plan that will allow us to improve all our financial indicators."

Pierre Morgon, Chairman of Theradiag’s Board of Directors, added: "Theradiag keeps on developing its Theranostics activity, which is the cornerstone of its growth strategy, and will remain agile by seizing any opportunities that arise on the IVD market. This strategy is enabling Theradiag to establish its leadership position on its key markets, which have excellent prospects."

Reminder of the main H1 2022 highlights

January 2022: Signing of a distribution agreement with BIOSYNEX of their AMPLIQUICK SARS-CoV-2 PCR test
May 2022: Launch of two new i-Tracker kits: i-Tracker Certolizumab and i-Tracker Anti-Certolizumab
May 2022: Launch of ez-Track1, a Point-of-Care Testing solution for therapeutic drug monitoring
June 2022: Partnership with Quotient Limited to advance autoimmune disease diagnostics
Next financial press release:

– H1 2022 results, on Monday September 19, 2022, before market